Comparative evaluation of acetaminophen form (I) in commercialized paracetamol brands

Oloyede, Oyedibu Oyebayo, Alabi, Zacchaeus Oluwatayo, Akinyemi, Amos Olalekan, Oyelere, Sunday Faith, Oluseye, Amuwaolorun Banky and Owoyemi, Bolaji Charles Dayo (2023) Comparative evaluation of acetaminophen form (I) in commercialized paracetamol brands. Scientific African, 19 . e01537. ISSN 2468-2276

[thumbnail of VOR]
Preview
PDF (VOR) - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

1MB

Official URL: https://doi.org/10.1016/j.sciaf.2022.e01537

Abstract

The vibrational spectroscopy (FT-IR/Raman) and X-ray diffraction techniques are combined alongside the principal component analysis (PCA) as novel integrated analytical techniques to comparatively investigate latent chemical information and quality discrepancies regarding twelve (12) commercialized paracetamol (APAP) brands. This research aim is to present an advanced computational screening approach using spectroscopic and X-ray diffraction techniques with PCA as a tool to investigate the structural properties of pharmaceutical solid drugs by vibrational mode and diffraction pattern analyzes. Herein, the acquired vibrational, absorption, and diffraction datasets of APAP functionalities were collected at spectra and diffraction regions of intense peaks to develop predictive PCA models. Interestingly, the PCA models invalidate drug falsification in all the brands and predicted dissimilarities arising from observed differences in the vibrational/absorption modes of APAP form (I) in some brands due to excessive use of cheap (fillers and hydrocolloid alternatives) excipients. The PCA-PXRD model unveils discrepancies regarding the contrasting diffraction patterns (structure-property relationships) observed for APAP form (I) in the brands, which suggests differences in their pharmacokinetic properties cause an unapparent structural modification. Nevertheless, the comparative drug release studies present a%CDR between 93 and 98% in 30 min for all the brands, thus, structural modifications of APAP form (I) as observed in some brands show no serious effects on the%CDR and/ or solubility. Finally, it is expected that this work will contribute to the advances in screening techniques toward addressing the global drug challenges, especially in developing countries.


Repository Staff Only: item control page